BRPI0502744B8 - processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente e processo para obter albumina - Google Patents

processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente e processo para obter albumina

Info

Publication number
BRPI0502744B8
BRPI0502744B8 BRPI0502744A BRPI0502744A BRPI0502744B8 BR PI0502744 B8 BRPI0502744 B8 BR PI0502744B8 BR PI0502744 A BRPI0502744 A BR PI0502744A BR PI0502744 A BRPI0502744 A BR PI0502744A BR PI0502744 B8 BRPI0502744 B8 BR PI0502744B8
Authority
BR
Brazil
Prior art keywords
albumin
pka
prekallikrein
activity
temporally
Prior art date
Application number
BRPI0502744A
Other languages
English (en)
Inventor
Ignacio Jorquera Nieto Juan
Hosta Mateu Nuria
Santaeularia Lozano Olga
Original Assignee
Grifols Sa
Probitas Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34072931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0502744(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa, Probitas Pharma Sa filed Critical Grifols Sa
Publication of BRPI0502744A publication Critical patent/BRPI0502744A/pt
Publication of BRPI0502744B1 publication Critical patent/BRPI0502744B1/pt
Publication of BRPI0502744B8 publication Critical patent/BRPI0502744B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente; processo para obter albumina; e solução purificada de albumina de origem humana com baixa atividade do ativador de pré-calicreína (pka) e com estabilidade temporal". a invenção descreve uma solução de albumina purificada de origem humana com baixa atividade do ativador de pré-calicreína (pka) e com estabilidade temporal, distinguida por ter um teor de antitrombina igual ou maior do que 0,03 mg/g de albumina, e um processo para a sua produção pela extração parcial da antitrombina durante o fracionamento do plasma humano.
BRPI0502744A 2004-07-26 2005-07-08 processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente e processo para obter albumina BRPI0502744B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401830 2004-07-26
ES200401830A ES2221817B1 (es) 2004-07-26 2004-07-26 "soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas".

Publications (3)

Publication Number Publication Date
BRPI0502744A BRPI0502744A (pt) 2006-05-02
BRPI0502744B1 BRPI0502744B1 (pt) 2019-02-26
BRPI0502744B8 true BRPI0502744B8 (pt) 2021-05-25

Family

ID=34072931

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0502744A BRPI0502744B8 (pt) 2004-07-26 2005-07-08 processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente e processo para obter albumina

Country Status (10)

Country Link
US (2) US7332577B2 (pt)
EP (1) EP1656954B2 (pt)
JP (1) JP4584788B2 (pt)
AU (1) AU2005202654B2 (pt)
BR (1) BRPI0502744B8 (pt)
DE (1) DE602005003426T3 (pt)
ES (2) ES2221817B1 (pt)
MX (1) MXPA05005915A (pt)
PL (1) PL1656954T4 (pt)
PT (1) PT1656954E (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101702334B1 (ko) * 2015-04-28 2017-02-06 동양피스톤 주식회사 피스톤용 냉각 튜브, 링 캐리어 어셈블리, 피스톤 및 이를 이용한 피스톤 제조 방법
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4251510A (en) * 1979-08-15 1981-02-17 Cutter Laboratories, Inc. Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
DE3622642A1 (de) 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
FR2610633B1 (fr) * 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
AT391810B (de) * 1988-02-26 1990-12-10 Immuno Ag Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators
FR2648048B1 (fr) * 1989-06-08 1994-06-03 Lille Transfusion Sanguine Procede de preparation de solutions d'albumine purifiee
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
WO1997031947A1 (en) * 1996-02-29 1997-09-04 Delta Biotechnology Limited High purity albumin production process
AU3624400A (en) * 1999-03-19 2000-10-09 Bayer Corporation Chromatographic albumin process
MXPA05005328A (es) * 2002-11-25 2005-08-16 Octapharma Ag Fraccion de albumina derivada de plasma con precalicreina empobrecida.

Also Published As

Publication number Publication date
DE602005003426D1 (de) 2008-01-03
JP2006036771A (ja) 2006-02-09
EP1656954B1 (en) 2007-11-21
ES2294664T5 (es) 2021-11-30
US20060020117A1 (en) 2006-01-26
US8084580B2 (en) 2011-12-27
ES2221817A1 (es) 2005-01-01
DE602005003426T2 (de) 2008-10-02
ES2221817B1 (es) 2005-10-01
BRPI0502744A (pt) 2006-05-02
PL1656954T4 (pl) 2008-08-29
EP1656954B2 (en) 2021-04-28
US20070161781A1 (en) 2007-07-12
US7332577B2 (en) 2008-02-19
JP4584788B2 (ja) 2010-11-24
PL1656954T3 (pl) 2008-04-30
AU2005202654B2 (en) 2007-04-05
DE602005003426T3 (de) 2021-09-02
AU2005202654A1 (en) 2006-02-09
EP1656954A1 (en) 2006-05-17
ES2294664T3 (es) 2008-04-01
PT1656954E (pt) 2008-02-14
BRPI0502744B1 (pt) 2019-02-26
MXPA05005915A (es) 2006-01-30

Similar Documents

Publication Publication Date Title
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
NO20052690D0 (no) Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
TW200505480A (en) High concentration antibody and protein formulations
GT199900072AA (es) Jarabe antihistaminico estabilizado
BRPI0519265A2 (pt) composiÇÕes incluindo ferro
BR9916678A (pt) Inibidores de trombina
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
BRPI0813139A8 (pt) peptídeo glp-1 com adição de cadeia oligossacarídea
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0307564A (pt) Derivados de nicotinamida úteis como inibidores de pde4
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ECSP055584A (es) Proceso para la preparación de fibrinógeno
EA200401365A1 (ru) Способы лечения илеуса
DK1581235T3 (da) Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE406903T1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
BRPI0419195A (pt) composição de lactato de mentila e uma mistura de isÈmeros de mentol
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
BRPI0502744B8 (pt) processo para reduzir a atividade do ativador de pré-calicreína (pka) em soluções de albumina purificada de origem humana e para estabilizá-la temporalmente e processo para obter albumina
WO2005002500A3 (en) Inhibitors of coronavirus
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
Fazavana et al. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity
BRPI0416461A (pt) método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2782 DE 30-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.